Reperfusion therapy for ST-elevation myocardial infarction complicated by cardiogenic shock: the European Society of Cardiology EurObservational programme acute cardiovascular care-European association of PCI ST-elevation myocardial infarction registry
- PMID: 35593654
- DOI: 10.1093/ehjacc/zuac049
Reperfusion therapy for ST-elevation myocardial infarction complicated by cardiogenic shock: the European Society of Cardiology EurObservational programme acute cardiovascular care-European association of PCI ST-elevation myocardial infarction registry
Abstract
Aims: To determine the current state of the use of reperfusion and adjunctive therapies and in-hospital outcomes in European Society of Cardiology (ESC) member and affiliated countries for patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS).
Methods and results: ESC EurObservational Research Programme prospective international cohort study of admissions with STEMI within 24 h of symptom onset (196 centres; 26 ESC member and 3 affiliated countries). Of 11 462 patients enrolled, 448 (3.9%) had CS. Patients with compared to patients without CS, less frequently received primary percutaneous coronary intervention (PCI) (65.5% vs. 72.2%) and fibrinolysis (15.9% vs. 19.0), and more often had no reperfusion therapy (19.0% vs. 8.5%). Mechanical support devices (intraaortic ballon pump 11.2%, extracoporeal membrane oxygenation 0.7%, other 1.1%) were used infrequently in CS. Bleeding definition academic research consortium 2-5 bleeding complications (10.1% vs. 3.0%, P < 0.01) and stroke (4.2% vs. 0.9%, P < 0.01) occurred more frequently in patients with CS. In-hospital mortality was 10-fold higher (35.5% vs. 3.1%) in patients with CS. Mortality in patients with CS in the groups with PCI, fibrinolysis, and no reperfusion therapy were 27.4%, 36.6%, and 62.4%, respectively.
Conclusion: In this multi-national registry, patients with STEMI complicated by CS less frequently receive reperfusion therapy than patients with STEMI without CS. Early mortality in patients with CS not treated with primary PCI is very high. Therefore, strategies to improve clinical outcome in STEMI with CS are needed.
Keywords: Cardiogenic shock; Primary percutaneous coronary intervention; Registry; Reperfusion therapy; ST-elevation myocardial infarction.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology.Eur Heart J. 2021 Nov 21;42(44):4536-4549. doi: 10.1093/eurheartj/ehab342. Eur Heart J. 2021. PMID: 34389857
-
The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry.Eur Heart J Qual Care Clin Outcomes. 2020 Apr 1;6(2):100-104. doi: 10.1093/ehjqcco/qcz042. Eur Heart J Qual Care Clin Outcomes. 2020. PMID: 31359068
-
Implementation of a Comprehensive ST-Elevation Myocardial Infarction Protocol Improves Mortality Among Patients With ST-Elevation Myocardial Infarction and Cardiogenic Shock.Am J Cardiol. 2020 Nov 1;134:1-7. doi: 10.1016/j.amjcard.2020.08.012. Epub 2020 Aug 15. Am J Cardiol. 2020. PMID: 32933753
-
Culprit Vessel-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment-Elevation Myocardial Infarction: A Collaborative Meta-Analysis.Circ Cardiovasc Interv. 2017 Nov;10(11):e005582. doi: 10.1161/CIRCINTERVENTIONS.117.005582. Circ Cardiovasc Interv. 2017. PMID: 29146672 Review.
-
Efficacy of Mechanical Circulatory Support Used Before Versus After Primary Percutaneous Coronary Intervention in Patients with Cardiogenic Shock From ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis.Cardiovasc Revasc Med. 2022 Sep;42:74-83. doi: 10.1016/j.carrev.2022.05.002. Epub 2022 May 6. Cardiovasc Revasc Med. 2022. PMID: 35570152
MeSH terms
Grants and funding
- Boston Scientific
- The Bristol Myers Squibb and Pfizer Alliance
- Daiichi Sankyo Europe GmbH
- The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company
- Edwards
- Gedeon Richter Plc
- Menarini Int. Op
- MSD-Merck & Co
- Novartis Pharma AG
- ResMed
- Sanofi
- SERVIER
- Vifor
- Abbott Vascular
- Gedeon Richter
- Novartis Pharma
LinkOut - more resources
Full Text Sources
Miscellaneous